Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

Needham upgraded Boston Scientific (BSX) to Buy from Hold with a $113 price target Needham’s latest electrophysiologist survey shows the ...

Needham upgraded Boston Scientific Corp (NYSE:BSX) to “Buy”, saying competition from pulsed field ablation (PFA) rivals looks less intense for its key product than it was earlier feared, and citing ...

Recent acquisitions are also seen as adding to Boston Scientific’s growth story. Bolt Medical’s new device for treating artery disease recently gained U.S. approval, while SoniVie is ...

The US stock market experienced a turbulent first quarter of 2025, marked by increased volatility and negative returns across the major indices.

Boston Scientific BSX is slated to report first-quarter 2025 results on April 23, before market open. For first-quarter 2025, Boston Scientific projects adjusted earnings in the range of 66-68 cents ...